Vimgreen’s Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
HANGZHOU, China, March 14, 2026 /PRNewswire/ -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval...
Read moreDetails